{"filing":{"accession_number":"0001395064-26-000183","cik":"0001395064","ticker":"TKPHF","company_name":"TAKEDA PHARMACEUTICAL CO LTD","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"form6k-2_062426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000183/form6k-2_062426.htm"},"events":[{"id":13340,"run_id":11845,"accession_number":"0001395064-26-000183","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit announces Julie Kim's appointment as Representative Director, President and CEO of Takeda following shareholder election and Board approval at the 150th Annual General Meeting. This is a material executive appointment of the company's chief executive officer, the most senior operational role. The disclosure also includes the concurrent retirement of former CEO Christophe Weber and appointments of three new external directors (Broussard, Kimura, Stoffels) and reassignments of existing directors to new committee roles, all effective June 24, 2026.","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":[{"id":10453,"accession_number":"0001395064-26-000183","item_number":"EX-99.1","item_title":"assignments.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces Julie Kim's appointment as Representative Director, President and CEO of Takeda following shareholder election and Board approval at the 150th Annual General Meeting. This is a material executive appointment of the company's chief executive officer, the most senior operational role. The disclosure also includes the concurrent retirement of former CEO Christophe Weber and appointments of three new external directors (Broussard, Kimura, Stoffels) and reassignments of existing directors to new committee roles, all effective June 24, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:08:01.048480+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10453,"accession_number":"0001395064-26-000183","item_number":"EX-99.1","item_title":"assignments.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit announces Julie Kim's appointment as Representative Director, President and CEO of Takeda following shareholder election and Board approval at the 150th Annual General Meeting. This is a material executive appointment of the company's chief executive officer, the most senior operational role. The disclosure also includes the concurrent retirement of former CEO Christophe Weber and appointments of three new external directors (Broussard, Kimura, Stoffels) and reassignments of existing directors to new committee roles, all effective June 24, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T10:08:01.048480+00:00","company_name":"TAKEDA PHARMACEUTICAL CO LTD","ticker":"TKPHF","filing_date":"2026-06-24"}]}